Literature DB >> 10938491

Health care costs of heart failure: results from a randomised study of patient education.

A B Linné1, H Liedholm, S Jendteg, B Israelsson.   

Abstract

BACKGROUND: Heart failure is a serious syndrome with a bad prognosis. Hospitalisation is common and readmittance rate is high; factors which influence the cost of care and treatment. Only scarce data on detailed patient materials regarding health care costs are known. AIMS: To describe in detail the health care costs for heart failure patients.
METHODS: Costs for patients (n=108) who completed a randomised education trial were studied for 6 months after hospital discharge. Costs for hospital stay, out-patient visits, diagnostic tests and procedures, laboratory analyses and drug treatment were calculated. Official unit prices list used to reimburse providers of cross-boundary health services and prices for drugs in the Swedish Drug Compendium were employed.
RESULTS: The total cost for a heart failure patient was approximately 20000 SEK (2564 US$, 7.80 SEK=1 US$) for 6 months. There was a 27-fold variation between patients. There was no relation between age or sex and cost. In decreasing order cost for hospitalisation was followed by costs for out-patient visits, diagnostic tests and procedures, laboratory analyses and drugs.
CONCLUSION: Hospitalisation was the largest part of the total cost and there was a large inter-individual variation. Efforts to reduce the economic burden should be focused on hospitalisation. Due to skewed distribution, individual data must be considered in the analysis of the efforts.

Entities:  

Mesh:

Year:  2000        PMID: 10938491     DOI: 10.1016/s1388-9842(00)00089-1

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  8 in total

Review 1.  Role of self-care in the patient with heart failure.

Authors:  Debra K Moser; Victoria Dickson; Tiny Jaarsma; Christopher Lee; Anna Stromberg; Barbara Riegel
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

Review 2.  The Stress-Response MAP Kinase Signaling in Cardiac Arrhythmias.

Authors:  Xun Ai; Jiajie Yan; Elena Carrillo; Wenmao Ding
Journal:  Rev Physiol Biochem Pharmacol       Date:  2016       Impact factor: 5.545

3.  Torasemide: a pharmacoeconomic review of its use in chronic heart failure.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Cost-effectiveness of eplerenone plus standard treatment compared with standard treatment in patients with myocardial infarction complicated by left ventricular systolic dysfunction and heart failure in the Netherlands.

Authors:  M L L van Genugten; W S Weintraub; Z Zhang; A A Voors
Journal:  Neth Heart J       Date:  2005-11       Impact factor: 2.380

Review 5.  Economic burden of heart failure in the elderly.

Authors:  Lawrence Liao; Larry A Allen; David J Whellan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  Symptom variability, not severity, predicts rehospitalization and mortality in patients with heart failure.

Authors:  Debra K Moser; Susan K Frazier; Linda Worrall-Carter; Martha J Biddle; Misook L Chung; Kyoung Suk Lee; Terry A Lennie
Journal:  Eur J Cardiovasc Nurs       Date:  2010-07-15       Impact factor: 3.908

Review 7.  SR calcium handling dysfunction, stress-response signaling pathways, and atrial fibrillation.

Authors:  Xun Ai
Journal:  Front Physiol       Date:  2015-02-19       Impact factor: 4.566

8.  Factors associated with prolonged hospitalization, readmission, and death in elderly heart failure patients in western Romania.

Authors:  Istvan Gyalai-Korpos; Oana Ancusa; Tiberiu Dragomir; Mirela Cleopatra Tomescu; Iosif Marincu
Journal:  Clin Interv Aging       Date:  2015-03-11       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.